Johnson & Johnson management check
JNJ · Health Care · Pharmaceuticals · CEO J. Duato
Filings as of
Closest peers in Pharmaceuticals
- 35LLYLilly (Eli)84
- 181JNJJohnson & Johnson70
- 195ZTSZoetis68
- 261MRKMerck & Co.64
- 277PFEPfizer63
- 335BMYBristol Myers Squibb59
- 369VTRSViatris57
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2022
2533rdDetail
$100 invested at the start of fiscal 2022 grew to $152, against $189 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9788thDetail
Over 4 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.93 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.1% of net income
What does the CEO cost owners?
$32.8m pay · $26.8bn net income, FY2025
100100thDetail
$32.8m of reported pay in fiscal 2025, against $26.8bn of net income.
- WatchCEO stake ≈ 3.2 years of pay
Do they own the stock?
399,258 shares ≈ $104.2m
6 mo: ▲ $0 bought · ▼ $73.9m sold
4044thDetail
The CEO holds 399,258 shares, directly or through trusts (unvested awards not counted): about 3.2 years of pay. 6 insiders sold $73.9m in the last six months and none bought.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −2.6% a year; flagged above +2%
Stock pay 1.4% of revenue
8274thDetail
Diluted shares changed -2.6% a year over the last three fiscal years. Stock-based pay was 1.4% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
8 filings under 8-K 5.02 in 3 years
CEOs: A. Gorsky, J. Duato
4521stDetail
CEOs in the pay table: A. Gorsky, J. Duato. 8 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 11, 2026.
Pay tied most to Annual relative total shareholder return
Other key measures•Operational sales•Three-year cumulative adjusted operational EPS•Adjusted operational EPS growth•Three-year TSR compound annual growth rate versus the competitor composite peer group•Free cash flow•Share price•Share price appreciation
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | J. Duato | $32.8m | $68.3m | $12.5m | $152 | $189 | $26.8bn |
| 2024 | J. Duato | $24.3m | $17.0m | $11.2m | $103 | $148 | $14.1bn |
| 2023 | J. Duato | $28.4m | $13.8m | $12.5m | $108 | $137 | $35.2bn |
| 2022 | A. Gorsky | $26.7m | $39.4m | $12.5m | $111 | $126 | $20.9bn |
Insiders and the CEO's stakeSelling
- CEO and Chairman of the Board
- Joaquin Duato
- Shares held
- 399,258
- At that filing's price
- ≈ $104.2m
- Latest Form 4
- Aug 13, 2026
6 insiders sold $73.9m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldJoaquin DuatoCEO and Chairman of the Board$44.7mAug 13, 2026
- SoldTimothy SchmidEVP, WW Chair, MedTech$9.2mSep 2, 2026
- SoldElizabeth ForminardEVP, Chief Legal Officer$7.8mNov 12, 2026
- SoldVanessa BroadhurstEVP, Global Corp Affairs$5.8mJul 20, 2026
Leadership and governance on file
All 17 filings
- Aug 4, 2026Leadership change8-K 5.02
- Sep 9, 2025Leadership change8-K 5.02
- Jun 10, 2025Leadership change8-K 5.02
- Apr 30, 2025Leadership change8-K 5.02
- Sep 10, 2024Leadership change8-K 5.02
- Aug 26, 2024Leadership change8-K 5.02
- Dec 5, 2023Leadership change8-K 5.02
- Nov 27, 2023Leadership change8-K 5.02
- Oct 23, 2023Leadership change8-K 5.02
- May 1, 2023Leadership change8-K 5.02
- Apr 3, 2023Leadership change8-K 5.02
- Feb 15, 2023Leadership change8-K/A 5.02
- Feb 14, 2023Leadership change8-K 5.02
- Dec 1, 2022Leadership change8-K 5.02
- Apr 29, 2022Leadership change8-K 5.02
- Feb 16, 2022Leadership change8-K 5.02
- Jan 6, 2022Leadership change8-K 5.02
Latest shareholder vote results: Apr 28, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $22.9bn returned to owners in buybacks and dividends, 20% of net income, and $6.0bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $78.7bn | $80.0bn | $85.2bn | $88.8bn | $94.2bn |
| Net income | $20.9bn | $17.9bn | $35.2bn | $14.1bn | $26.8bn |
| Stock-based pay | $1.1bn | $1.1bn | $1.2bn | $1.2bn | $1.4bn |
| Buybacks | $3.5bn | $6.0bn | $5.1bn | $2.4bn | $6.0bn |
| Dividends | — | — | — | — | — |
| Diluted shares | 2674m | 2664m | 2560m | 2429m | 2429m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.